103 related articles for article (PubMed ID: 27721577)
1. Elevated Expression of Programmed Death-1 and Programmed Death Ligand-1 Negatively Regulates Immune Response against Cervical Cancer Cells.
Chen Z; Pang N; Du R; Zhu Y; Fan L; Cai D; Ding Y; Ding J
Mediators Inflamm; 2016; 2016():6891482. PubMed ID: 27721577
[TBL] [Abstract][Full Text] [Related]
2. Percentages of PD-1
Wang Y; Pang N; Wang X; Liu Y; Wang X; Wang L; Sun M; Yasen H; Zhao F; Fan W; Guo X; Ding J
Hum Vaccin Immunother; 2018 Apr; 14(4):832-838. PubMed ID: 29333980
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of PD-L1 in Cervical Cancer Patients and the Potential for Combining an Immune Checkpoint Inhibitor With Lenvatinib.
Bräutigam K; Schmidt T; Baur M; Tauber N; Kontomanolis EN; Hemptenmacher F; Rody A; Köster F
Anticancer Res; 2024 Feb; 44(2):503-510. PubMed ID: 38307554
[TBL] [Abstract][Full Text] [Related]
4. Targeting PI3Kα increases the efficacy of anti-PD-1 antibody in cervical cancer.
Jiang W; Ouyang X; Li C; Long Y; Chen W; Ji Z; Shen X; Xiang L; Yang H
Immunology; 2023 Nov; 170(3):419-438. PubMed ID: 37469254
[TBL] [Abstract][Full Text] [Related]
5. Adenosine increases PD-L1 expression in mesenchymal stromal cells derived from cervical cancer through its interaction with A
Marín-Aquino LA; Mora-García ML; Moreno-Lafont MC; García-Rocha R; Montesinos-Montesinos JJ; López-Santiago R; Sánchez-Torres LE; Torres-Pineda DB; Weiss-Steider B; Hernández-Montes J; Don-López CA; Monroy-García A
Cell Biochem Funct; 2024 Apr; 42(3):e4010. PubMed ID: 38613217
[TBL] [Abstract][Full Text] [Related]
6. Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations.
Zerdes I; Matikas A; Bergh J; Rassidakis GZ; Foukakis T
Oncogene; 2018 Aug; 37(34):4639-4661. PubMed ID: 29765155
[TBL] [Abstract][Full Text] [Related]
7. Relationships between intravoxel incoherent motion parameters and expressions of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) in patients with cervical cancer.
Liu KH; Yang W; Tian HP
Clin Radiol; 2024 Feb; 79(2):e264-e272. PubMed ID: 37926648
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Potential of Targeting Transforming Growth Factor-beta (TGF-β) and Programmed Death-ligand 1 (PD-L1) in Pancreatic Cancer.
Pourali G; Zafari N; Velayati M; Mehrabadi S; Maftooh M; Hassanian SM; Mobarhan MG; Ferns GA; Avan A; Khazaei M
Curr Drug Targets; 2023; 24(17):1335-1345. PubMed ID: 38053355
[TBL] [Abstract][Full Text] [Related]
9. Association of CDKN2A/B mutations, PD-1, and PD-L1 with the risk of acute lymphoblastic leukemia in children.
Ruan Y; Xie L; Zou A
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10841-10850. PubMed ID: 37314514
[TBL] [Abstract][Full Text] [Related]
10. Ezrin Modulates the Cell Surface Expression of Programmed Cell Death Ligand-1 in Human Cervical Adenocarcinoma Cells.
Tanaka C; Kobori T; Tameishi M; Urashima Y; Ito T; Obata T
Molecules; 2021 Sep; 26(18):. PubMed ID: 34577118
[TBL] [Abstract][Full Text] [Related]
11. Precision medicine for cervical cancer.
Manrriquez EN; Zakhour M; Salani R
Curr Opin Obstet Gynecol; 2022 Feb; 34(1):1-5. PubMed ID: 34596094
[TBL] [Abstract][Full Text] [Related]
12. Adenosine Increases the Immunosuppressive Capacity of Cervical Cancer Cells by Increasing PD-L1 Expression and TGF-β Production through Its Interaction with A
García-Rocha R; Monroy-García A; Vázquez-Cruz AL; Marín-Aquino LA; Weiss-Steider B; Hernández-Montes J; Don-López CA; Molina-Castillo G; Mora-García ML
Pharmaceuticals (Basel); 2024 Mar; 17(3):. PubMed ID: 38543183
[TBL] [Abstract][Full Text] [Related]
13. A study of programmed death-1/programmed death ligand and iodine-induced autoimmune thyroiditis in NOD.H-2h4 mice.
Li F; Zhou Z; Wang L; Li B; Jin M; Liu J; Chen Y; He Y; Ren B; Shen H; Liu L
Environ Toxicol; 2023 Nov; 38(11):2574-2584. PubMed ID: 37598415
[TBL] [Abstract][Full Text] [Related]
14. Advanced detection of cervical cancer biomarkers using engineered filamentous phage nanofibers.
Zhou X; Wang Y; Bao M; Chu Y; Liu R; Chen Q; Lin Y
Appl Microbiol Biotechnol; 2024 Feb; 108(1):221. PubMed ID: 38372795
[TBL] [Abstract][Full Text] [Related]
15. Manipulating TGF-β signaling to optimize immunotherapy for cervical cancer.
Yin S; Cui H; Qin S; Yu S
Biomed Pharmacother; 2023 Oct; 166():115355. PubMed ID: 37647692
[TBL] [Abstract][Full Text] [Related]
16. Bifunctional Blockade: A Novel Immunotherapy Approach for Cervical Cancer.
Miller KM; Friedman CF
Clin Cancer Res; 2022 Dec; 28(24):5238-5240. PubMed ID: 35947045
[TBL] [Abstract][Full Text] [Related]
17. Targeting cervical cancer with anti-PD-1 antibodies: what is new?
Greenman M; McNamara B; Mutlu L; Santin AD
Expert Opin Biol Ther; 2024 Mar; 24(3):111-114. PubMed ID: 38391293
[No Abstract] [Full Text] [Related]
18. Expression of Programmed Death Receptor Ligand 1 with High Tumor-Infiltrating Lymphocytes Is Associated with Better Prognosis in Breast Cancer.
Bae SB; Cho HD; Oh MH; Lee JH; Jang SH; Hong SA; Cho J; Kim SY; Han SW; Lee JE; Kim HJ; Lee HJ
J Breast Cancer; 2016 Sep; 19(3):242-251. PubMed ID: 27721873
[TBL] [Abstract][Full Text] [Related]
19. CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia.
Semaan A; Dietrich D; Bergheim D; Dietrich J; Kalff JC; Branchi V; Matthaei H; Kristiansen G; Fischer HP; Goltz D
Virchows Arch; 2017 Feb; 470(2):185-196. PubMed ID: 27913861
[TBL] [Abstract][Full Text] [Related]
20. Elevated PD-L1 expression predicts poor survival outcomes in patients with cervical cancer.
Gu X; Dong M; Liu Z; Mi Y; Yang J; Zhang Z; Liu K; Jiang L; Zhang Y; Dong S; Shi Y
Cancer Cell Int; 2019; 19():146. PubMed ID: 31143091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
